Company news
Soligenix, Inc. (NASDAQ:SNGX) news
Soligenix, Inc. news releases on 6ix. Latest, Jan 7, 2021: Soligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301…
Press releases — page 4
Soligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301 Companion Light Device in the Treatment of Cutaneous T-Cell Lymphoma
January 6, 2021
Soligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development
December 27, 2020
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
December 21, 2020
Soligenix Announces $20 Million Strategic Convertible Debt Financing Agreement with Pontifax Medison Debt Financing
December 15, 2020
Soligenix Demonstrates Extended Protection with its RiVax® Ricin Toxin Vaccine
December 7, 2020
Soligenix Announces Recent Accomplishments And Third Quarter 2020 Financial Results
November 11, 2020
Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma
October 21, 2020
Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens
September 14, 2020
Soligenix Announces Recent Accomplishments And Second Quarter 2020 Financial Results
August 13, 2020
Soligenix Announces Publication of Positive Pre-clinical Results for a Novel COVID-19 Vaccine
July 27, 2020
Soligenix Issues Corporate Update - Highlights Important Catalysts for Second Half of 2020
July 19, 2020
Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis
June 23, 2020
Soligenix to Join Russell Microcap® Index
June 21, 2020
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
May 14, 2020
Soligenix Announces Publication of Correlates of Immune Protection for the RiVax® Ricin Toxin Vaccine
May 10, 2020
Soligenix Receives $840,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
May 6, 2020
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
April 29, 2020
Soligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals
April 15, 2020
Soligenix Receives European Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma
April 5, 2020
Soligenix Announces Recent Accomplishments And Year-End 2019 Financial Results
March 29, 2020
Soligenix Announces Positive Top-line Results for its Pivotal Phase 3 FLASH Trial Evaluating SGX301 in Treatment of Cutaneous T-Cell Lymphoma
March 18, 2020
Soligenix Announces Successful Demonstration of Heat Stabilization for Filovirus Vaccine Platform
February 26, 2020
FDA Grants Soligenix "Fast Track" Designation for RiVax® in the Prevention of Ricin Poisoning
February 12, 2020
Soligenix Announces SGX301 Patient Case Study Presentation at the 4th World Congress of Cutaneous Lymphomas
February 10, 2020
Soligenix Announces Japanese Patent Allowance for Use of Dusquetide in Oral Mucositis
February 2, 2020
Soligenix Initiates Clinical Trial of its Heat Stable Ricin Toxin Vaccine
December 11, 2019
Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX301 in the Treatment of Cutaneous T-cell Lymphoma
December 2, 2019
Soligenix Announces Recent Accomplishments And Third Quarter 2019 Financial Results
November 11, 2019
Soligenix Receives US Patent for Improved Production of Synthetic Hypericin Composition
October 23, 2019
Soligenix Appoints Daniel P. Ring as Vice President of Business Development and Strategic Planning
September 15, 2019
Soligenix Appoints Jonathan Guarino as Chief Financial Officer
September 10, 2019
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer
August 27, 2019
Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications
August 14, 2019
Soligenix Announces Recent Accomplishments And Second Quarter 2019 Financial Results
August 12, 2019
Soligenix Announces Appointment of Diane L. Parks to its Board of Directors
July 7, 2019
Soligenix Announces $600,000 Subaward Supporting Evaluation of Innate Defense Regulator Platform Technology as a Medical Countermeasure for Bacterial Threat Agents
May 27, 2019
Soligenix Announces Recent Accomplishments And First Quarter 2019 Financial Results
May 13, 2019
Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer
April 17, 2019
Soligenix Receives $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
April 14, 2019
Soligenix and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for SGX942
April 8, 2019
Soligenix Receives US Patent for Dusquetide Related Analogs
April 3, 2019